These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 1587641)
1. Improved immunoglobulin production in dialysis patients treated with recombinant erythropoietin. Schaefer RM; Paczek L; Berthold G; Gilge U; Heidland A Int J Artif Organs; 1992 Apr; 15(4):204-8. PubMed ID: 1587641 [TBL] [Abstract][Full Text] [Related]
2. [Numerical and functional alterations in T and B lymphocyte subpopulations in CAPD patients treated with recombinant human erythropoietin]. Tanabe R Nihon Jinzo Gakkai Shi; 1994 Oct; 36(10):1159-68. PubMed ID: 7815748 [TBL] [Abstract][Full Text] [Related]
3. Improved function of B lymphocytes in dialysis patients treated by recombinant human erythropoietin. Paczek L; Schaefer RM; Heidland A Contrib Nephrol; 1990; 87():36-41. PubMed ID: 2093539 [No Abstract] [Full Text] [Related]
4. Suppression of immunoglobulin and interleukin-6 production from peripheral blood mononuclear cells by dialysis membranes. Paczek L; Schafer RM; Teschner M; Heidland A ASAIO Trans; 1990; 36(3):459-61. PubMed ID: 2252806 [TBL] [Abstract][Full Text] [Related]
5. Effect of beta 2-microglobulin on immunoglobulin production. Paczek L; Czarkowska B; Schaefer L; Schaefer RM; Heidland A Immunol Lett; 1992 Jun; 33(1):87-91. PubMed ID: 1427994 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of immunoglobulin production by parathyroid hormone. Implications in chronic renal failure. Gaciong Z; Alexiewicz JM; Linker-Israeli M; Shulman IA; Pitts TO; Massry SG Kidney Int; 1991 Jul; 40(1):96-106. PubMed ID: 1921161 [TBL] [Abstract][Full Text] [Related]
7. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. Ifudu O; Feldman J; Friedman EA N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143 [TBL] [Abstract][Full Text] [Related]
8. Dialysis membranes decrease immunoglobulin and interleukin-6 production by peripheral blood mononuclear cells in vitro. Paczek L; Schaefer RM; Heidland A Nephrol Dial Transplant; 1991; 6 Suppl 3():41-4. PubMed ID: 1775266 [TBL] [Abstract][Full Text] [Related]
9. [The effect of short-term erythropoietin therapy on selected parameters of cell mediated and humoral immunity in hemodialyzed uremic patients]. Wiecek A; Kyrcz-Krzemień S; Franek E; Kokot F; Hołowiecki J; Klin M Pol Arch Med Wewn; 1995 Jan; 93(1):41-7. PubMed ID: 7479217 [TBL] [Abstract][Full Text] [Related]
10. Immunoenzymatic determination of immunoglobulins secreted by human peripheral blood lymphocytes in pokeweed mitogen and lipo-polysaccharide stimulated cultures. Quintiliani L; Iudicone P; Guglielmetti M; Buzzonetti A Boll Ist Sieroter Milan; 1984 Jul; 63(3):188-95. PubMed ID: 6391518 [TBL] [Abstract][Full Text] [Related]
11. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Maiorca R Clin Nephrol; 1990 Dec; 34(6):272-8. PubMed ID: 2073771 [TBL] [Abstract][Full Text] [Related]
12. Long-term effects on lymphocytotoxic antibodies and immune reactivity in hemodialysis patients treated with recombinant human erythropoietin. Bárány P; Fehrman I; Godoy C Clin Nephrol; 1992 Feb; 37(2):90-6. PubMed ID: 1551255 [TBL] [Abstract][Full Text] [Related]
13. Normalization of serum prolactin levels in hemodialysis patients on recombinant human erythropoietin. Schaefer RM; Kokot F; Kuerner B; Zech M; Heidland A Int J Artif Organs; 1989 Jul; 12(7):445-9. PubMed ID: 2767790 [TBL] [Abstract][Full Text] [Related]
14. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. London GM; Zins B; Pannier B; Naret C; Berthelot JM; Jacquot C; Safar M; Drueke TB Kidney Int; 1989 Nov; 36(5):878-82. PubMed ID: 2615194 [TBL] [Abstract][Full Text] [Related]
15. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596 [TBL] [Abstract][Full Text] [Related]
17. Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations. Steffensen G; Aunsholt NA; Povlsen JV Clin Nephrol; 1996 Feb; 45(2):98-103. PubMed ID: 8846537 [TBL] [Abstract][Full Text] [Related]
18. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients. Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168 [TBL] [Abstract][Full Text] [Related]
19. [The effect of treatment with human recombinant erythropoietin on the functional status of patients on maintenance hemodialysis]. Ermolenko VM; Lashutin SV; Rudakov AG; Fel'd BN; Manakova TE; Kukhtevich AV; Kondakhchan MA; Romanenko NG Ter Arkh; 1991; 63(6):81-6. PubMed ID: 1948755 [TBL] [Abstract][Full Text] [Related]
20. Use of recombinant human erythropoietin (rh-EPO) in the treatment of anemia in hemodialysis patients: a multicenter Italian experience. Buccianti G; Colombi L; Battistel V Haematologica; 1993; 78(2):111-7. PubMed ID: 8349186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]